Document is current

Documents that mention this clinical trial

SAT0165 PRECLINICAL AND CLINICAL CHARACTERIZATION OF CENERIMOD, A POTENT, SELECTIVE, AND ORALLY ACTIVE SPHINGOSINE-1-PHOSPHATE RECEPTOR 1 MODULATOR IN SLE
https://doi.org/10.1136/annrheumdis-2020-eular.503

First use of cenerimod, a selective S1P₁ receptor modulator, for the treatment of SLE: a double-blind, randomised, placebo-controlled, proof-of-concept study
https://doi.org/10.1136/lupus-2019-000354

POS1408 TARGETING KEY COMPONENTS OF SLE PATHOGENESIS WITH THE MULTIFACETED IMMUNOMODULATORY PROPERTIES OF CENERIMOD, A SELECTIVE S1P1 RECEPTOR MODULATOR
https://doi.org/10.1136/annrheumdis-2024-eular.3025

LO-016 The multifaceted immunomodulatory properties of cenerimod, a selective S1P1 receptor modulator, target three key aspects of SLE pathogenesis
https://doi.org/10.1136/lupus-2023-kcr.16

O38 Preclinical and clinical characterization of cenerimod, a potent, selective, and orally active sphingosine-1-phosphate receptor 1 modulator in SLE
https://doi.org/10.1136/lupus-2020-eurolupus.49

P138 Preclinical and clinical characterization of cenerimod, a potent, selective, and orally active sphingosine-1-phosphate receptor 1 modulator in SLE
https://doi.org/10.1136/lupus-2020-eurolupus.182

Documents that mention this clinical trial

SAT0165 PRECLINICAL AND CLINICAL CHARACTERIZATION OF CENERIMOD, A POTENT, SELECTIVE, AND ORALLY ACTIVE SPHINGOSINE-1-PHOSPHATE RECEPTOR 1 MODULATOR IN SLE
https://doi.org/10.1136/annrheumdis-2020-eular.503

PO:11:303 Transcriptional changes associated with cenerimod therapy, a selective S1PR1 modulator, in systemic lupus erythematosus: results from the placebo controlled Phase 2b CARE trial
https://doi.org/10.1136/lupus-2026-el.356

First use of cenerimod, a selective S1P₁ receptor modulator, for the treatment of SLE: a double-blind, randomised, placebo-controlled, proof-of-concept study
https://doi.org/10.1136/lupus-2019-000354

PT4:03 Effect of cenerimod, an S1P1 modulator, on fatigue in SLE: results from the phase 2 care study
https://doi.org/10.1136/lupus-2026-el.50

POS1147 EFFICACY OF CENERIMOD IN PATIENTS WITH HIGH IFN-1 GENE EXPRESSION SIGNATURE AND HIGH ANTI-DSDNA ANTIBODY LEVELS: POST-HOC ANALYSIS FROM A PHASE 2 STUDY
https://doi.org/10.1136/annrheumdis-2023-eular.3823

POS1408 TARGETING KEY COMPONENTS OF SLE PATHOGENESIS WITH THE MULTIFACETED IMMUNOMODULATORY PROPERTIES OF CENERIMOD, A SELECTIVE S1P1 RECEPTOR MODULATOR
https://doi.org/10.1136/annrheumdis-2024-eular.3025

LO-016 The multifaceted immunomodulatory properties of cenerimod, a selective S1P1 receptor modulator, target three key aspects of SLE pathogenesis
https://doi.org/10.1136/lupus-2023-kcr.16

OP0293 PHARMACODYNAMIC EFFECTS OF THE SELECTIVE S1P1 RECEPTOR MODULATOR CENERIMOD ON THE BLOOD TRANSCRIPTOME OF PATIENTS WITH SLE
https://doi.org/10.1136/annrheumdis-2024-eular.5111

O38 Preclinical and clinical characterization of cenerimod, a potent, selective, and orally active sphingosine-1-phosphate receptor 1 modulator in SLE
https://doi.org/10.1136/lupus-2020-eurolupus.49

AB0024 IN VITRO CHARACTERIZATION OF CENERIMOD, A POTENT AND SELECTIVE SPHINGOSINE 1-PHOSPHATE RECEPTOR 1 (S1P1) MODULATOR IN PREVENTING MIGRATION OF NON-ACTIVATED AND ACTIVATED PRIMARY HUMAN B CELLS IN THE PRESENCE OR ABSENCE OF GLUCOCORTICOIDS
https://doi.org/10.1136/annrheumdis-2021-eular.2482

P138 Preclinical and clinical characterization of cenerimod, a potent, selective, and orally active sphingosine-1-phosphate receptor 1 modulator in SLE
https://doi.org/10.1136/lupus-2020-eurolupus.182

LSO-092 Safety, efficacy and pharmacodynamics of cenerimod in patients with systemic lupus erythematosus: two randomised, double-blind phase 2 clinical trials
https://doi.org/10.1136/lupus-2023-kcr.133

THU0008 DEVELOPMENT OF A NOVEL TRANSLATIONAL IN SILICO INDICATION DISCOVERY FRAMEWORK: EXEMPLIFIED BY THE CLINICAL COMPOUND CENERIMOD
https://doi.org/10.1136/annrheumdis-2020-eular.3520